Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Douglas Loe Research Report 15 November $8.50 Target
View:
Post by askretka on Nov 15, 2022 9:28pm

Douglas Loe Research Report 15 November $8.50 Target

https://leedejonesgable.com/wp-content/uploads/ONC_2022_11_15.pdf -------------------------- Post KOL, lots off good info here. Cheers!!!!!!!!!!
Comment by Buckhenry on Nov 15, 2022 9:44pm
what century are they predicting that. we have had some over the last 2 years predicting over 10 so pardon me if I don't get all gitty. just more BS.
Comment by hsbc11 on Nov 16, 2022 12:55am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities